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Abstract MicroRNAs (miRs) are small non- coding
RNA molecules controlling a plethora of biological
processes such as development, cellular survival and
senescence. We here determined miRs differentially
regulated during cardiac postnatal development and
aging. Cardiac function, morphology and miR expres-
sion profiles were determined in neonatal, 4 weeks,
6 months and 19 months old normotensive male
healthy C57/Bl6N mice. MiR-22 was most prominent-
ly upregulated during cardiac aging. Cardiac expres-
sion of its bioinformatically predicted target mimecan
(osteoglycin, OGN) was gradually decreased with ad-
vanced age. Luciferase reporter assays validated mim-
ecan as a bona fide miR-22 target. Both, miR-22 and
its target mimecan were co- expressed in cardiac fibro-
blasts and smooth muscle cells. Functionally, miR-22
overexpression induced cellular senescence and pro-
moted migratory activity of cardiac fibroblasts. Small
interference RNA-mediated silencing of mimecan in
cardiac fibroblasts mimicked the miR-22-mediated
effects. Rescue experiments revealed that the effects
of miR-22 on cardiac fibroblasts were only partially
AGE (2013) 35:747–762
DOI 10.1007/s11357-012-9407-9
This work was presented at the XXX Annual Meeting of the
European Section of the International Society of Heart Research
in Haifa, Israel (26.01- 01.07.2011).
Electronic supplementary material The online version of this
article (doi:10.1007/s11357-012-9407-9) contains
supplementary material, which is available to authorized users.
V. Jazbutyte : J. Fiedler :A. Just :A. Holzmann :
T. Thum (*)
Institute of Molecular and Translational Therapeutic
Strategies (IMTTS), IFB-Tx, Hannover Medical School,
Carl-Neuberg-Str. 1,
30625 Hannover, Germany
e-mail: thum.thomas@mh-hannover.de
URL: http://www.mh-hannover.de/imtts.html
S. Kneitz
Microarray Core Facility, Interdisciplinary
Centre of Clinical Research, University of Würzburg,
Würzburg, Germany
P. Galuppo : J. Bauersachs
Department of Cardiology and Angiology,
Hannover Medical School,
Hannover, Germany
T. Thum
Centre for Clinical and Basic Research,
IRCCS San Raffaele,
Rome, Italy
mediated by mimecan. In conclusion, miR-22 upregu-
lation in the aging heart contributed at least partly to
accelerated cardiac fibroblast senescence and in-
creased migratory activity. Our results suggest an in-
volvement of miR-22 in age-associated cardiac
changes, such as cardiac fibrosis.
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Introduction
Physiological aging and senescence are associated to
progressive decline in most physiological functions,
reduced response to stress, loss of viability and in-
creased susceptibility to various diseases (Lakatta and
Sollott 2002; Selvamurthy et al. 1999). Cardiac aging is
associated with reduced cardiac functional reserve, left
ventricular hypertrophy, mild fibrosis and reduced en-
dogenous cardiac protection (Dai and Rabinovitch
2009; Jahangir et al. 2007). The incidence of cardiovas-
cular disease increases dramatically with advanced age,
therefore elucidation of the molecular mechanisms con-
tributing to cardiac aging in healthy heart would help to
identify early pathophysiological changes in the heart.
Early diagnostics of cardiovascular disease might help to
improve currently available therapies and develop new
more efficient treatment strategies. The proposed mech-
anisms which are responsible for cardiac aging involve
genetic and environmental factors, such as a decrease in
telomerase activity and shortening of the DNA of the
telomeres (Fuster and Andres 2006; Kajstura et al. 2006),
increased oxidative stress (Terman and Brunk 2006),
loss of mitochondrial function (Dai and Rabinovitch
2009) and impaired autophagy (Terman et al. 2007). In
the last decade epigenetic regulators, such as small non-
coding RNAs, called.g. microRNAs (miRs), were
shown to be involved in cellular aging processes (Li et
al. 2009; Williams et al. 2007). MiRs are endogenous
22-24 nt long RNA molecules which suppress target
protein expression either by promoting messenger
RNA (mRNA) degradation or by translational repres-
sion (Bauersachs and Thum 2011; Brodersen and
Voinnet 2009). MiRs are highly conserved and account
1-5 % of worm, plant and vertebrate genomes (Blakaj
and Lin 2008; Laporte et al. 2007). It is hypothesized
that up to 90 % of human genes are regulated by
microRNAs (Perron and Provost 2008). According to
“microRNA.org” database (http://www.microrna.org/
microrna/releaseNotes.do#GeneralInformation; August
2010 release), there are about 1100 human miRs with
known sequences which are involved in nearly every
developmental and cell function process, such as organ-
ogenesis and cell cycle, cell survival, apoptosis, migra-
tion and differentiation (Crespi and Frugier 2008; Fazi
and Nervi 2008; Liu 2009; Thum et al. 2008a; Zhao and
Srivastava 2007). MiRs are involved not only in phys-
iological processes but are also major players in the
onset and development of various diseases, such as
cancer, immunological pathologies, neurodegenerative
diseases and cardiovascular pathologies (Coolen and
Bally-Cuif 2009; da Costa Martins et al. 2010; Dai and
Ahmed 2011; Ferracin et al. 2010; Thum et al. 2008b).
MiRs substantially contribute to the development of
cardiac pathologies and their ability to influence gene
networks suggest miRs as potential therapeutic targets
and/ or diagnostic markers (Fichtlscherer et al. 2010;
Thum et al. 2008b; Wang et al. 2010).
Here, we aimed to identify age- associated changes
in miR expression profile in the murine heart and
analyze prominent postnatally expressed and also
aging-associated miRs. Additionally, we aimed to dis-
sect molecular mechanisms and pathways that are
regulated by aging- associated miRs in cardiac cells,
especially cardiac fibroblasts.
Results
Morphometric and functional analysis of postnatal
murine hearts during aging
Cardiac function andmorphometric parameters of 4weeks,
6 months and 19 months old animals were estimated by
non- invasive echocardiography. Cardiac parameters, such
as end- systolic area (ESA), and- diastolic area (EDA),
interventricular septum thickness (IVS) and posterior wall
thickness (PW) were significantly increased in aged ani-
mals compared to the parameters of 4 weeks old (control)
animals (Table 1) Functional cardiac parameters, such as
fractional shortening (FS) and heart rate (HR) remained
unchanged between the groups (data not shown). Due to
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very small size of the neonatal mice (mean body weight
1.26±0.013 g and mean heart weight 5.59±0.3 mg), we
here were not able to perform non-invasive echocardi-
ography measurements. Morphometric measurements
showed that absolute and relative heart weight gradually
increased with advanced age (Table 2). Thus, echocar-
diography and morphometric measurements indepen-
dently demonstrated age- dependent development of
physiological hypertrophy in healthy male mouse
hearts.
Collagen content measurements in 4 weeks old,
6 months and 19 months old mouse hearts revealed
marginal collagen accumulation in 4 weeks and
6 months old mouse hearts and significantly increased
cardiac fibrosis in 19 months old animals (3.8 % vs.
1.3 % in 4 weeks old hearts, p<0.01) as depicted in
Fig. 1a. Lipofuscin accumulation in the myocardium
served as an independent parameter for cardiac senes-
cence. Lipofuscin deposition started at the age of six
months and reached its maximum in 19 months old
hearts (Fig. 1, panel b). Senescence associated p53 and
p16 levels were also increased during cardiac aging
(Fig. 1, panel c).
MicroRNA profiling in neonatal and postnatal murine
hearts
MicroRNA expression profiles in hearts of neonatal,
4 weeks old, 6 months and 19 months old mice were
assessed using a miR array approach (data not shown).
We then used a set of neonatal, 4 weeks old, 6 months
and 19 months old mice for further validation analyses.
MiR-22 and miR-24 were highly upregulated, whereas
miR-351 and miR-542-5p were significantly downregu-
lated in post-natal hearts compared to neonatal controls
(Fig. 2). For further analysis, we focused on miR-22
whose expression positively correlated with advanced
age in the various studied groups (Fig. 2). Various
cardiac cell types, such as neonatal rat cardiomyocytes,
human cardiac fibroblasts, smooth muscle cells and
endothelial cells were analyzed for miR-22 expression
levels. MiR-22 was enriched in cardiac fibroblasts and
smooth muscle cells, whereas lower miR-22 levels were
observed in cardiomyocytes and endothelial cells
(Fig. 3a).
Mimecan is a direct target of miR-22 in the mouse
heart
To identify miR-22 targets, we first performed com-
putational miR target analysis. Three microRNA tar-
get prediction programs (PicTar, TargetScan and
microRNA.org) revealed mimecan (osteoglycin) as a
potential miR-22 target gene. We performed mimecan
protein expression analysis in the mouse hearts of
different age groups and observed mimecan to be
highly expressed in the neonatal heart but gradually
decreased during cardiac aging (Fig. 3b). Indeed, ex-
pression levels of miR-22 and mimecan showed a
highly significant inverse correlation (r0-0.76, p<
0.0052) suggesting that mimecan may be a target for
miR-22 in the heart (Fig. 3c).
Direct mimecan regulation by miR-22 was ana-
lyzed using a luciferase reporter gene approach. Two
luciferase reporter gene constructs carrying either
wild-type (wt) 3’- UTR of murine mimecan gene
(OGN) or mutant (mut) 3’-UTR carrying three nucle-
otide changes within the miR-22 binding site of OGN
3’- UTR, were generated to analyze miR-22 binding to
Table 1 Cardiac parameters measured by non- invasive echocardiography
Groups Systole, AP ESA [mm2] Diastole, AP EDA [mm2] IVS [cm] PW [cm]
4 weeks 0.038±0.003 0.077±0.005 0.119±0.006 0.061±0.007
6 months 0.059±0.004 0.110±0.004 0.150±0.007 0.089±0.005
19 months 0.056±0.006 0.106±0.006 0.154±0.006 0.093±0.003
Statistically significant parameters versus 4 weeks old animals (control group), p< 0.05
Table 2 Absolute and relative heart weight
Groups Abs. HW [mg] rel. HW [mg/ mm tibia]
Neonatal 5.59±0.3
4 weeks 80.03±1.6 5.15±0.1
6 months 137.54±8.13 7.67±0.51
19months 127.06±3.63 7.13±0.19
Statistically significant parameters versus neonatal animals (abs.
HW) and 4 weeks old animals (rel. HW), p< 0.05
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wt and mut OGN 3’- UTRs (Fig. 4a). HEK293 cells
were co- transfected with either wt or mut OGN 3’-
UTR together with miR-22 precursors (pre-miR-22) or
control precursor miRs (preNeg2). Luciferase activity
was assessed 24 hours post-transfection and normal-
ized against beta- galactosidase activity. The results
showed that overexpressed miR-22 efficiently down-
regulated OGN wt 3’-UTR luciferase reporter activity
reaching approximately 40 % compared to control
miRs (Fig. 4a, left panel). In contrast, mutation of
three nucleotides in miR-22 binding site in the OGN 3’-
UTR (OGN mut) abrogated miR-22 precursor- depen-
dent reduction of luciferase reporter activity (Fig. 4a,
right panel). We further studied mimecan protein
expression changes after miR-22 modulation in cardiac
fibroblasts which were transfected with control miR
(preNeg2), miR-22 precursor (pre-miR-22) or miR-22
Fig. 2 Postnatally differentially regulated microRNAs. Differen-
tially expressed microRNAs in hearts from neonatal, 4 months,
6 months and 19 months old male Bl6 mice. MiR-22 and miR-24
were strongly upregulated whereas miR-351 and miR-542-5p
were significantly downregulated in postnatal compared to neona-
tal hearts. Data are expressed as mean ± SEM (n08/ group). *, p<
0.05; **, p<0.01; ***, p<0.001
Fig. 1 Cardiac fibrosis and aging (lipofuscin deposition, p53 and
p16 expression). Cardiac fibrosis was visualized by picrosirius red
(PSR) staining where collagen fibers are red whereas myocardium
is stained in yellow. The degree of cardiac fibrosis is expressed as
percentage of collagen signal versus total signal intensity (chart in
Fig. 1a ). Representative PSR stainings are shown in the middle
panel. Deposition of autofluorescent lipofuscin particles was ob-
served in 4 % PFA fixated cryosections using fluorescence filter at
594 nm wavelength range (lower panel). Quantification data of
lipofuscin signal intensity in cardiac sections are expressed as
percentage of lipofuscin signal versus total signal intensity (chart,
Fig. 1b). c Protein expression of senescence-associated p53 and
p16 in cardiac tissue. Data in the chart are expressed as mean ±
SEM (n04 tissues/sections/ group); **, p<0.01; ***, p<0.001
R
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antagonist (anti-miR-22). Overexpression of miR-22 in
cardiac fibroblasts resulted in significant decrease in
mimecan expression whereas inhibition of endoge-
nous miR-22 in fibroblasts did not affect mimecan
expression (Fig. 4b). Next, we analyzed mimecan
localization pattern in the mouse heart and observed
mimecan to partially co-localize with cardiac fibroblasts
and within perivascular areas (Fig. 4c, inlays a-c) as well
as with smooth muscle cells, which were located in larger
cardiac vessels (Fig. 4c,inlays d-f). In contrast, there was
no co-localization between mimecan and endothelial
cells or cardiomyocytes (Fig. 4c, inlays g-i and data not
shown).
In conclusion, we identified cardiac miR-22/mim-
ecan co-expression and validated mimecan to be a
direct target of miR-22 in cardiac fibroblasts.
MiR- 22 and mimecan regulate cellular senescence
and chemotaxis
To determine which cellular functions might be
affected by miR-22, we studied potential changes
in cellular senescence, chemotaxis, proliferation,
apoptosis and cell migration of cardiac fibroblasts.
To assess cellular senescence, we analyzed senescence-
associated beta galactosidase (SA-β- Gal) activity
in neonatal rat cardiac fibroblasts and human
Fig. 3 MiR-22 and mimecan expression in the aging heart. a
MiR-22 expression in rat cardiac myocytes, human cardiac
fibroblasts, umbilical cord endothelial cells and smooth muscle
cells showed miR-22 enrichment in cardiac fibroblasts and
smooth muscle cells (n03- 4/ group). b Protein expression levels
of the miR-22 predicted target mimecan in hearts from aging mice.
cNegative correlation betweenmiR-22 andmimecan in the mouse
hearts depicted by regression analysis with a Pearson’s correlation
coefficient of r0-0.74 (p00.0052). Data are expressed as mean SQ
± SEM. *, p<0.05; **, p<0.01; ***, p<0.001
R
Fig. 4 Mimecan is regulated by miR-22 and localized in the
mouse heart. a Luciferase reporter vector carrying either wild-
type (left panel) or mutant human mimecan 3’- UTR (right
panel) was co-transfected with control miR (preNeg2) or miR-
22 precursor (pre-miR22). Luciferase activity results were nor-
malized versus beta galactosidase activity in the same cells. b
MiR-22 overexpression resulted in significant mimecan protein
downregulation in cardiac fibroblasts, whereas inhibition of
endogenous miRNA by sequence- specific antagonist did not
influence mimecan expression. Representative mimecan west-
ern blots are shown in b, right panel. c Immunofluorescent
staining of mimecan protein expression (green) in the murine
heart. Mimecan was partially co- localized with cardiac fibro-
blasts (red) (panels a-c) and smooth muscle cells (red) (smooth
muscle actin (SMA) staining) (panels d-f) but not with endothe-
lial cells (red) (marker CD31) (g-i). Cell nuclei were stained
with DAPI. The pictures were taken at 200x magnification. Data
are expressed as mean ± SEM (n03-5/ group). **, p<0.01
b
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cardiac fibroblasts (HCFs). MiR-22 overexpression
in neonatal cardiac fibroblasts resulted in a signif-
icant increase in senescent cells whereas inhibition
of this miR by a sequence-specific antagonist did not
affect cellular aging (Fig. 5a). MiR-22-mediated in-
crease in cellular senescence could be mimicked by
mimecan silencing where mimecan-deficient fibroblasts
were more prone to premature senescence compared to
Fig. 5 Effects of miR-22 on cellular senescence. Neonatal rat and
adult human cardiac fibroblasts were transfected with miR-22
precursor (pre-miR-22), miR-22 antagonist (antimiR-22) or con-
trol miR (preNeg2) (a, c). To determine enzymatic activity of
senescence-associated beta galactosidase (SA-β- Gal), cells were
fixed and incubated withβ- Gal substrate. Blue color intensity was
analyzed and data was expressed as ratio between treatment and
control group. MiR-22 overexpression significantly induced pre-
mature senescence in neonatal rat cardiac fibroblasts (a). Mimecan
(osteoglycin, OGN) silencing using sequence- specific siRNA
induced cellular senescence in neonatal fibroblasts mimicking
the effects of miR-22 overexpression (b). Adult cardiac fibroblasts
expressed high endogenous levels of miR-22, thus overexpression
of this microRNA resulted in marginal increase in cellular senes-
cence, whereas miR-22 inhibition reduced it (c). Mimecan (OGN)
silencing increased cellular senescence in adult cardiac fibroblasts
(d). Data are expressed as mean ± SEM (n04-5/ group). *, p<0.05
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control-siRNA transfected fibroblasts (Fig. 5b). In adult
cardiac fibroblasts, which express high levels of endog-
enous miR-22, ectopic overexpression of miR-22 only
slightly affected cellular aging. However, suppression of
endogenous miR-22 using miR-22 specific antagonist
significantly reduced SA-β- Gal positive cell number
indicating that miR-22 directly contributes to cellular
senescence (Fig. 5c). Mimecan silencing similarly
upregulated cellular senescence in cardiac fibroblasts
thus mimicking the miR-22 effects (Fig. 5d). There
was a trend for increased expression of senescence-
associated p16 expression in cardiac fibroblasts over-
expressing miR-22 or after mimecan silencing
(Supplementary Figure 1a and b). We next constructed
experiments to test the direct role of mimecan for the
miR-22-mediated effects in cardiac fibroblast. The effi-
ciency of mimecan knockdown / viral overexpression
was assessed by western blotting as indicated in
Supplementary Figure 2. First, miR-22 depletion
efficiently reduced cellular senescence but additional
silencing of mimecan had no rescuing effects
(Supplementary Figure 3a). Second, in adult fibroblasts
overexpressing miR-22, the co-transfection of a miR-
22-resistant mimecan construct only partly rescued the
effects on cellular senescence (Supplementary
Figure 3b). These results point to miR-22 as an impor-
tant regulator of cellular senescence and that only parts
of its effects are directly mediated via mimecan. This is
likely as a single miR may have hundreds of different
targets and thus further targets mediating miR-22 effects
in cardiac fibroblasts remains to be determined.
Fibroblast chemotactic activity was assessed using
a modified Boyden chamber assay. We transfected
neonatal and adult cardiac fibroblasts with control
miR, miR-22 precursor or miR-22 antagonist, and let
the cells migrate towards 20 % FCS. Both neonatal
and adult cardiac fibroblasts overexpressing miR-22
showed up to 150 % increased chemotactic migratory
activity compared to control cells (Fig. 6a-d). To test
the influence of mimecan in the miR-22-mediated
effects on fibroblast chemotactic activity we first si-
lenced miR-22 via treatment with anti-miR-22. This
resulted in a trend for lower migratory activity and
additional silencing of mimecan via siRNA had only
little effect (Supplementary Figure 4a). Next, we over-
expressed miR-22 leading to increased chemotactic
activity. Co-transfection with a miR-22-resistant form
of mimecan did not reverse the pro-chemotactic
effects of miR-22 (Supplementary Figure 4b). Both
experiments show that miR-22 effects on chemotactic
activity are independent of mimecan.
We also tested the effects of miR-22 overexpression
in smooth muscle cells, where we observed a high
senescence- associated β-Gal activity whereas miR-22
inhibition reduced cellular senescence in this cell type
(Supplementary Figure 5a). A similar increase in che-
motactic migration was observed in smooth muscle cells
overexpressing miR-22 (Supplementary Figure 5b).
Another cell migration assay, the scratch wound as-
say, was performed to test, whether miR-22 influences
cell migration independent from chemotactic stim-
uli. To prevent cell proliferation, mitomycin C was
added to the cell culture medium. Here, we did
not find differences in cell migration in neonatal
or adult fibroblasts (data not shown). Likewise,
cell proliferation and cell apoptosis/necrosis meas-
urements indicated no significant functional changes in
all treatment groups and both cell types (data not
shown).
In conclusion, we here show miR-22 upregulation
during cardiac aging and demonstrated that miR-22
selectively regulates cellular senescence and cellular
chemotactic migration in cardiac fibroblasts which
may contribute to miR-22 dependent cardiac fibrosis
during aging.
Discussion
In our study, we demonstrate for the first time that
miR-22 contributes to cardiac aging by influencing
cardiac fibroblasts. It was recently demonstrated that
miRs, such as miR-19b, miR-20a and miR-106a were
differentially regulated in old human cells, such as
endothelial cells, CD8+ T- cells, renal epithelial cells
and skin fibroblasts (Hackl et al. 2010). Van Almen
and colleagues demonstrated that the members of
miR-17-92 cluster, miR-18a, -19a and -19b, target
extracellular proteins such as connective tissue growth
factor (CTGF) and thrombospondin-1 (TSP-1) which
were upregulated in old failing hearts (van Almen et
al. 2011). Other miRs, such as miR-21 and the mem-
bers of miR-29 family, were shown to be involved in
extracellular matrix remodeling in the heart where
miR-21 promoted fibrosis and miR-29 family members
were negative regulators of cardiac fibrosis following
myocardial infarction (Thum et al. 2008b; van Rooij et
al. 2008).
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The approach of miR screening in the heart
revealed several miRs whose expression was tightly
associated with the cardiac aging. MiR-22 expression
was progressively increasing with advanced age sug-
gesting a role in cardiac aging. We identified mime-
can/ osteoglycin (OGN) as a novel target for miR-22
in the mouse heart. Mimecan is a secretory protein
which belongs to small leucin- rich proteoglycan family
and was first described together with TGF-β1 and TGF-
β2 to be involved in ectopic bone formation (Bentz et al.
1989; Madisen et al. 1990). Later, mimecan was
detected not only in the bone, but also in the vascular
matrix (Shanahan et al. 1997), cornea (Dunlevy et al.
2000), skin (Tasheva et al. 2002), the auditory system
(Williamson et al. 2008) and other organs. In the present
study we show that mimecan is expressed in the mouse
heart with highest expression levels in the neonatal hearts
and its expression gradually decreases with advanced age
due to increased miR-22 expression. Mimecan localiza-
tion studies showed that mimecan was co-expressed with
miR-22 in cardiac fibroblasts and smooth muscle cells
but we could not detect significant mimecan expression
in cardiomyocytes, as described recently (Petretto et al.
2008). The variations of mimecan localization in the
cardiac cells might be species-specific.
We could induce premature senescence in neonatal rat
cardiac fibroblasts bymiR-22 overexpression. Our results
are in agreement with recently published data where
miR-22 was shown to be upregulated in human senescent
fibroblasts and epithelial cells and downregulated in
Fig. 6 Chemotactic migratory capacity of cardiac fibroblasts is
mediated by miR-22. Neonatal rat and adult human cardiac
fibroblasts were transfected with miR-22 precursor, antagonist
and control miR (preNeg 2). Chemotactic migration assay was
performed using modified Boyden chamber approach where
cells migrated through semi- permeable membrane towards
20 % FCS. Migrated cells were stained with DAPI and counted.
The mean number of migrated neonatal fibroblasts transfected
with control miRNA was set to 1 and the ratios between pre-
miR-22 and anti-miR-22 versus group and control are depicted
in panel a. MiR-22- induced chemotactic activity of fibroblasts
could be mimicked by mimecan (Ogn) knockdown in neonatal
fibroblasts (b). Similarly, ectopic expression of miR-22 in adult
fibroblasts also resulted in significant increase in chemotaxis (c)
and these effects could be reproduced by mimecan (Ogn) knock-
down (panel d, p00.055). Data are expressed as mean ± SEM
(n04-5/ group). *, p<0.05
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various cancer cell lines (Xu et al. 2011a). The authors
also identified CDK6, SIRT1 and Sp1 as miR-22 targets
and postulated that miR-22 act as tumor suppressor. We
studied SIRT1 as putative protein target for miR-22 in the
heart and determined endogenous SIRT1 levels in all four
age groups but could not find significant differences
during aging (data not shown). However, there might
be additional functions of this miR in other cardiac cell
types, such as cardiomyocytes. Indeed, miR-22 overex-
pression also results in cardiomyocyte hypertrophy
(Jentzsch et al. 2011; Xu et al. 2011b), although this is
not the topic of the present manuscript where we mainly
focused on cardiac fibroblasts. Indeed our data showed
thatmiR-22 overexpression increased cellular senescence
which is in a good agreement with recently published
data (Xu et al. 2011a). However, we only observed a
trend for senescence-associated p16 in fibroblasts after
mir-22 overexpression or mimecan silencing potentially
suggesting longer time periods are needed to fully induce
a senescence-associated phenotype (Supplementary
Figure 1). In contrast to the described anti-proliferative
capacity of miR-22 in hepatocellular carcinoma cells, we
did not observed any changes in cell proliferation follow-
ing miR-22 modulation in cardiac fibroblasts and smooth
muscle cells suggesting cell-type specific effects (Zhang
et al. 2010).We found that cardiac fibroblasts and smooth
muscle cells overexpressing miR-22 demonstrated en-
hanced chemotactic migration. This data suggests that
miR-22- dependent cell movements are rather cell sur-
face receptor dependent than based on cell- cell inter-
actions as we did not see migration differences as in a
(chemotactic independent) scratch wound migration as-
say. Indeed, data about the role of chemotaxis in the
aging heart are sparse. In contrast, there is much infor-
mation about chemotaxis in the context of inflammation
events associated with cardiovascular disease (Madorin
et al. 2004). Mimecan depletion in neonatal and adult
cardiac fibroblasts mimicked the effects of miR-22 over-
expression showing accelerated cellular aging and in-
creased chemotaxis. However, whereas parts of the
effects of miR-22 on cellular senescence might be me-
diated via mimecan, its effects on fibroblast-mediated
activity were mimecan-independent. Thus, further, as
yet unidentified, targets of miR-22 are likely to be
involved in its fibroblast-specific effects.
Taken together, we demonstrate that cardiac miR-22
and mimecan expression was tightly associated with
cardiac aging. We show that both molecules affect fi-
broblast aging and are involved in fibroblast activation
without affecting cell proliferation and apoptosis. Future
in vivo and in vitro studies are required to assess further
molecular mechanisms of cardiac aging which are af-
fected by miR-22 and its downstream target mimecan.
Whether miR-22 based treatment strategies would affect
cardiac aging and/or cardiac fibrosis is a challenging
questions that awaits future analysis.
Experimental procedures
Materials and chemicals
A detailed list of the materials and chemicals used in
this study is presented in Supplementary data.
Mice
This study was approved by the local animal care
committee of the local government (Regierung
Unterfranken; Germany). The studies were performed
in accordance with the guidelines published by the US
National Institutes if Health (NIH publication Nr. 85-
23, revised 1996). Male C57/Bl6N mice (4 weeks old,
6 months old and 19 months old) were obtained from
Charles River Wiga GmbH (Sulzfeld, Germany).
Neonatal mice (1-2 days old) were obtained from the
animal facility of the University Clinics in Würzburg,
Germany. The 4 weeks old, 6 months old and 19months
old mice were kept for one week under standard day/
night cycle, the animals became standard chow and
water ad libitum. Cardiac function and heart size was
monitored by non-invasive echocardiography which
was performed by a trained person. Morphometric data,
such as cardiac weight, body weight, lung weight and
tibia length were collected to analyze cardiac morpho-
metric parameter changes during the aging. For molec-
ular analysis and histological studies, the hearts were
explanted, weighted and cut in three pieces which were
stored in liquid nitrogen for RNA and protein extraction
or frozen in TissueTec for histological analysis.
Cell culture
Human cardiac fibroblasts (HCF) were cultivated in
Fibroblast Basal medium supplemented with 5 % and
human aortic smooth muscle cells (HASMC) were
grown in SmbM2 medium supplemented with hFGF4,
insulin and 10 % FCS. Neonatal rat cardiac fibroblasts
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and HEK293 cells were cultivated in DMEM medium
containing 10 % FCS. For starvation experiments, the
cells were cultivated in the respective medium without
supplements, such as growth factors, and with 1/10th of
the initial FCS concentration for 24 h before begin of the
experiments.
In vivo studies
Cardiac function and heart size was monitored by
non- invasive echocardiography. Briefly, animals were
placed on heating pad, anesthesized by isoflurane and
oxygen mixture and cardiac dimensions and function
were assessed by pulse- wave Doppler echocardiogra-
phy using Toshiba PowerVision6000 system and a
15 MHz transducer. Cardiac parameters, such systolic
and diastolic area, interventricular septum and posterior
wall thickness as well as functional parameters, such as
heart rate and fractional shortening were measured to
assess cardiac hypertrophy and function. The data
were analyzed using NICE TOS- eBASE software
(ToshibaMedical Systems, The Netherlands) in a blinded
fashion.
RNA preparation
Total RNA from the mouse heart was extracted using
Trizol® reagent according to the manufacturer’s rec-
ommendations. Briefly, frozen tissue was homogenized
in Trizol and total heart RNAwas extracted as described
in the protocol. RNA quality was assessed using 2100
Bioanalyzer from Agilent in combination with Agilent
RNA 6000 Nano Kit. High quality total RNA was
further process to enrich microRNAs. MicroRNA en-
richment was performed using flashPAGE Fractionator
Sytem (Ambion) according to manufacturer’s protocol.
Enriched small- molecular weight RNA was further
subjected to microRNA arrays. Total RNA from cells
and cardiac tissue was extracted using Trizol® reagent
according to standard protocol, the RNA quality and
concentration was defined spectrophotometrically and
the samples were kept at -80°C.
MicroRNA arrays
MicroRNA expression profile in the neonatal, juve-
nile, adult and senescent mouse hearts was analyzed
using microRNA arrays containing “mirVana™
miRNA probe set”. Three arrays per age group were
hybridized with the RNA probes where each probe
contained pooled RNA from three animals from the
same group. MicroRNA samples were labeled using
“mirVANA™ miRNA labeling kit” and hybridized
with microRNA arrays according to the manufacturer’s
recommendations. Densitometric analysis (gridding)
was performed using free software “ScanAlyze”
(Stanford University, USA), and statistical data analysis
was performed by blinded person (statistics with “R”).
The microRNAs which were at least 1.5- fold differen-
tially regulated compared to microRNAs from neonatal
(control) group, were selected for further analyses.
Quantitative PCR (qPCR)
Differentially regulated microRNAs were validated by
quantitative real-time PCR and Taqman assays. Briefly,
first- strand DNA synthesis using microRNA specific
primers was performed using iScript™ Select cDNA
synthesis system. The microRNA signal was amplified
and detected using iQ™ Supermix and microRNA- spe-
cific TaqMan® MicroRNA probe under standard condi-
tions described by Bio-Rad. The microRNA expression
results were normalized against house keeping gene,
RNU6B, and the data was analyzed using ΔΔC(t) and
starting quantity methods.
Western blotting
Western blotting was performed as described other-
wise. Briefly, heart tissue was homogenized in lysis
buffer containing protease inhibitors and DTT, centri-
fuged and protein concentrations were measured using
Bradford method. Total protein (40 μg) was loaded on
polyacrylamide gel, separated under reducing condi-
tions and transferred to PVDF membrane. After trans-
fer, the membranes were blocked with 5 % non- fat
milk solution and incubated overnight with primary
antibodies against Mimecan, SIRT1 and GAPDH at
concentration 1 μg/ ml. Next day, the membranes were
washed with TBS/T and incubated with anti- goat and
anti- mouse HRP- conjugated secondary antibodies for
one hour at room temperature, washed with TBS/T,
incubated with ECL reagent and visualized using X-
ray film. The X-ray film was developed, scanned and
the signal was quantified using “Scion Image” free-
ware (Scion Corporation). Protein of interest signal
was normalized versus house keeping gene GAPDH.
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Picrosirius red staining
Collagen content in mouse heart cryosections was
visualized by picrosirius red staining according to the
standard protocols. Cryosections were fixed with 37 %
formaldehyde and incubated in picrosirius red solution
for 1 h. Subsequently, the sections were rinsed with
diluted acetic acid and, washed with water and mounted
with Entellan. The percentage of collagen content in the
sections was determined densitometrically using Adobe
Photoshop CS3 software.
Lipofuscin visualization
Mouse heart cryosections were dried, fixed 10 minutes
with 4 % paraformaldehyde (PFA) solution and mounted
with Vectashield medium containing DAPI. Lipofuscin
autofluorescence and DAPI was observed at 600 nm and
460 nm, respectively and photographed using Nikon Ti
microscope. Lipofuscin signal quantificationwas performed
using Adobe Photoshop CS3 software and expressed as
percentage of red signal versus global pixel number.
Immunohistochemistry
Cardiac tissue samples were frozen in Tissue-Tek®
O.C.T. compound, cut in 5- 10 μm cryosections, placed
on SuperFrost Plus slides and air- dried. The sections
were fixed with 4 % PFA and permeabilized with 0.1 %
Triton X-100. Subsequently, unspecific background was
blocked with 5 % donkey serum and sections were
incubated overnight with goat- anti- mimecan, rat- anti-
fibroblast marker, rat- anti- CD31 diluted in 5 % donkey
serum at concentration 3-5 μg/ml. Next day, the sections
were washed with PBS and incubated with the
fluorescence- conjugated secondary antibodies (donkey-
anti- goat AlexaFluor 488, donkey- anti- rat AlexaFluor
594 and donkey anti- rabbit AlexaFluor 594) together
with DAPI for nuclear staining. The sections were
mounted using VectaShield® mounting medium, covered
with cover slips and subjected to fluorescencemicroscopy.
Fluorescence microscopy pictures were taken by Nikon Ti
fluorescence microscope and analyzed using NIS-
Elements BR 3.2 software (Nikon corp.).
Cell transfection
HCFs, neonatal rat cardiac fibroblasts and HASMCs were
transfected with miR-22 precursor or miR-22 antagonist
together with the scrambled control (100 nM) as well as
siRNA against human osteoglycin and control siRNA
(3.3 nM of each duplex and end concentration of
10 nM) using Lipofectamine 2000 reagent. The proce-
dure was performed as described by manufacturer. The
cells were transfected for 72 h and subsequently sub-
jected to further cellular assays.
Adenoviral transduction
Human cardiac fibroblasts were infected with an adeno-
virus carrying the human OGN gene under control of
CMV promoter (Ad-OGN). The viral construct was ap-
plied following 4 hour transfection with miR-22 precur-
sors and/or antagonists and the cells were incubated in
diluted adenovirus overnight. Working concentration of
adenovirus was 250 MOI, which was determined during
serial dilution experiments. The cells were transduced/
transfected for 72 hours and subsequently subjected to
various cellular assays. Anadenovirus carrying the GFP
gene under control of CMV promoter served as a nega-
tive control for the Ad-OGN construct. The efficiency of
osteoglycin (mimecan) overexpression in cardiac fibro-
blasts is demonstrated in Supplementary Figure 2.
Luciferase reporter gene assay
Murine OGN 3´-UTR (fragment of 569 bp) containing
a miR binding site for miR-22 was PCR amplified and
cloned into SpeI and HindIII digested pMIR-REPORT
vector. For mutagenesis of the miR-22 binding site,
the QuikChange Multi Site-Directed Mutagenesis Kit
was applied according to manufacturers´ instructions.
The resulting construct was co-transfected with miRs
and beta-galactosidase control plasmid into HEK293
reporter cells in 48-wells using Lipofectamine 2000,
20 ng plasmid DNA and 100 nM miR. Cells were
incubated for 24 h before measuring luciferase and
β-galactosidase activity with appropriate substrates.
Senescence- associated beta galactosidase
(SA-β- Gal) assay
SA-β- Gal activity at pH 6.0 was histochemically detected
using Senescence-β- Galactosidase assay according to
manufacturer’s instructions. Briefly, the cells were grown
in 6- well plates, transfected and 72 h later, fixed with 1x
Fixative solution and incubated overnight in staining
solution containing X-gal. Next day, staining solution
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was discarded and cells coated with 70% glycerol. Cells
were photographed at 10× magnification using Nikon Ti
microscope and blue signal intensity was quantified
densitometrically. Briefly, the .bmp images were ana-
lyzed using Adobe Photoshop CS3 software where in-
tensity of the blue color i.e. SA-b-Gal signal was
assessed. The pictures from one experiment were ana-
lyzed using the same settings and differences between
treatment groups and control group was expressed as a
ratio versus control group which was set to one. Five
areas of each well representing one experimental condi-
tion were photographed and quantified. Mean signal
intensity of four and more independent experiments was
analyzed statistically.
Chemotaxis assay (modified Boyden chamber)
Prior to the assay, transfected cells were stained with
DAPI directly in the cell culture plate, trypsinized,
counted and 50000 cells were applied to the HTS
Fluoro Block inserts with the 8 μm pore size which
outer side of the membrane was coated with fibronec-
tin. The cells migrated towards cell culture medium
containing 20 % FCS for 24 hours or shorter, if indi-
cated otherwise. The fluorescence microscopy pictures
were taken by Nikon Ti fluorescence microscope, the
nuclei in the pictures were counted by blinded person.
Each treatment group was tested in triplets and mean
numbers of migrated cells of three and more indepen-
dent experiments were analyzed statistically.
Scratch wound assay
The cells were cultivated in 6- well plates and scratch
in cell monolayer was performed using 100 μl pipette
tip. The cells were kept in the cell culture medium
containing mitomycin C (5 μg/ ml) to prevent cell
proliferation. Scratches were photographed at timepoint
zero (0 h), after 6 hours and 24 hours. Scratch area was
estimated using NIS Elements BR 3.2 software and the
ratio between scratch area at timepoints 6 hours and
24 hours served as surrogate parameter for cell migra-
tion capacity. The influence of miR-22 and Ogn modu-
lation on cell migration was assessed comparing scratch
area of miR-22 and Ogn si- modulated cells at one
timepoint versus respective negative controls which
were set to 100 %. The results are presented as percent
difference between control and treatment group.
Cell proliferation assay
Cell proliferation capacity was determined usingWST-1
reagent. Briefly, the cells were seeded in 96- well plates,
transfected and grown for 72 hours. Before cell treat-
ment, WST-1 reagent was diluted in the cell culture
medium at final concentration 1:10 and immediately
applied to the cells. The absorbance at time points zero
minutes, 30minutes and 1 hour was measured at 450 nm
wave-length using a microplate reader Synergy HT
(Biotek, Bad Friedrichshall, Germany). Cell proliferation
rate was calculated as a ratio between 1 hour and 30 min.
and timepoint zero and compared between different treat-
ment groups.
Apoptosis assay
Apoptotic cells were stained using Annexin-V- FLUOS
Staining system according to manufacturer’s recom-
mendations. Apoptotic cell detection was performed
using flow cytometer FACSCalibur (BD Biosciences,
Heidelberg, Germany) and quantitative analysis was
performed using CellQuest™ software.
Statistics
Statistical analysis was performed using SigmaStat 2.0
software (Systat GmbH) where, dependent on the group
number, ANOVA or t-test were applied. The post-hoc
analyses were used in combination with ANOVA:
A P value<0.05 was considered as statistically
significant.
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